Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 18 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 11 |
NetGPI | no | yes: 0, no: 11 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005741 | mitochondrial outer membrane | 5 | 1 |
GO:0005886 | plasma membrane | 3 | 1 |
GO:0016020 | membrane | 2 | 1 |
GO:0019867 | outer membrane | 3 | 1 |
GO:0031090 | organelle membrane | 3 | 1 |
GO:0031966 | mitochondrial membrane | 4 | 1 |
GO:0031968 | organelle outer membrane | 4 | 1 |
GO:0098588 | bounding membrane of organelle | 4 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 1 |
Related structures:
AlphaFold database: A4HDS7
Term | Name | Level | Count |
---|---|---|---|
GO:0006629 | lipid metabolic process | 3 | 12 |
GO:0008152 | metabolic process | 1 | 12 |
GO:0044238 | primary metabolic process | 2 | 12 |
GO:0071704 | organic substance metabolic process | 2 | 12 |
GO:0006066 | alcohol metabolic process | 3 | 1 |
GO:0006576 | biogenic amine metabolic process | 5 | 1 |
GO:0006580 | ethanolamine metabolic process | 5 | 1 |
GO:0006644 | phospholipid metabolic process | 4 | 1 |
GO:0006793 | phosphorus metabolic process | 3 | 1 |
GO:0006796 | phosphate-containing compound metabolic process | 4 | 1 |
GO:0006807 | nitrogen compound metabolic process | 2 | 1 |
GO:0009308 | amine metabolic process | 4 | 1 |
GO:0009987 | cellular process | 1 | 1 |
GO:0019637 | organophosphate metabolic process | 3 | 1 |
GO:0034308 | primary alcohol metabolic process | 4 | 1 |
GO:0042439 | ethanolamine-containing compound metabolic process | 4 | 1 |
GO:0044237 | cellular metabolic process | 2 | 1 |
GO:0044255 | cellular lipid metabolic process | 3 | 1 |
GO:0044281 | small molecule metabolic process | 2 | 1 |
GO:0070291 | N-acylethanolamine metabolic process | 5 | 1 |
GO:1901160 | primary amino compound metabolic process | 4 | 1 |
GO:1901564 | organonitrogen compound metabolic process | 3 | 1 |
GO:1901615 | organic hydroxy compound metabolic process | 3 | 1 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 12 |
GO:0008081 | phosphoric diester hydrolase activity | 5 | 12 |
GO:0016787 | hydrolase activity | 2 | 12 |
GO:0016788 | hydrolase activity, acting on ester bonds | 3 | 12 |
GO:0042578 | phosphoric ester hydrolase activity | 4 | 12 |
GO:0008889 | glycerophosphodiester phosphodiesterase activity | 6 | 1 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 163 | 165 | PF00675 | 0.323 |
CLV_NRD_NRD_1 | 187 | 189 | PF00675 | 0.399 |
CLV_NRD_NRD_1 | 260 | 262 | PF00675 | 0.323 |
CLV_NRD_NRD_1 | 99 | 101 | PF00675 | 0.353 |
CLV_PCSK_KEX2_1 | 149 | 151 | PF00082 | 0.283 |
CLV_PCSK_KEX2_1 | 163 | 165 | PF00082 | 0.215 |
CLV_PCSK_KEX2_1 | 187 | 189 | PF00082 | 0.392 |
CLV_PCSK_KEX2_1 | 259 | 261 | PF00082 | 0.338 |
CLV_PCSK_KEX2_1 | 328 | 330 | PF00082 | 0.396 |
CLV_PCSK_KEX2_1 | 99 | 101 | PF00082 | 0.270 |
CLV_PCSK_PC1ET2_1 | 149 | 151 | PF00082 | 0.383 |
CLV_PCSK_PC1ET2_1 | 328 | 330 | PF00082 | 0.440 |
CLV_PCSK_SKI1_1 | 146 | 150 | PF00082 | 0.376 |
CLV_PCSK_SKI1_1 | 2 | 6 | PF00082 | 0.474 |
CLV_PCSK_SKI1_1 | 261 | 265 | PF00082 | 0.454 |
CLV_PCSK_SKI1_1 | 44 | 48 | PF00082 | 0.240 |
DEG_Nend_UBRbox_1 | 1 | 4 | PF02207 | 0.481 |
DOC_CKS1_1 | 279 | 284 | PF01111 | 0.491 |
DOC_CKS1_1 | 300 | 305 | PF01111 | 0.441 |
DOC_MAPK_gen_1 | 187 | 195 | PF00069 | 0.260 |
DOC_MAPK_gen_1 | 73 | 83 | PF00069 | 0.260 |
DOC_MAPK_gen_1 | 99 | 106 | PF00069 | 0.293 |
DOC_PP4_FxxP_1 | 300 | 303 | PF00568 | 0.426 |
DOC_USP7_MATH_1 | 242 | 246 | PF00917 | 0.226 |
DOC_USP7_MATH_1 | 26 | 30 | PF00917 | 0.334 |
DOC_USP7_MATH_1 | 86 | 90 | PF00917 | 0.177 |
DOC_WW_Pin1_4 | 278 | 283 | PF00397 | 0.461 |
DOC_WW_Pin1_4 | 299 | 304 | PF00397 | 0.432 |
LIG_Actin_WH2_2 | 136 | 151 | PF00022 | 0.398 |
LIG_Actin_WH2_2 | 7 | 22 | PF00022 | 0.481 |
LIG_AP2alpha_1 | 83 | 87 | PF02296 | 0.398 |
LIG_APCC_ABBA_1 | 80 | 85 | PF00400 | 0.260 |
LIG_FHA_1 | 117 | 123 | PF00498 | 0.260 |
LIG_FHA_1 | 153 | 159 | PF00498 | 0.374 |
LIG_FHA_1 | 171 | 177 | PF00498 | 0.143 |
LIG_FHA_1 | 199 | 205 | PF00498 | 0.345 |
LIG_FHA_1 | 262 | 268 | PF00498 | 0.335 |
LIG_FHA_2 | 103 | 109 | PF00498 | 0.329 |
LIG_FHA_2 | 124 | 130 | PF00498 | 0.260 |
LIG_LIR_Apic_2 | 298 | 303 | PF02991 | 0.400 |
LIG_LIR_Gen_1 | 294 | 305 | PF02991 | 0.454 |
LIG_LIR_Nem_3 | 160 | 165 | PF02991 | 0.260 |
LIG_LIR_Nem_3 | 294 | 300 | PF02991 | 0.493 |
LIG_LIR_Nem_3 | 324 | 330 | PF02991 | 0.518 |
LIG_Pex14_2 | 83 | 87 | PF04695 | 0.398 |
LIG_SH2_CRK | 327 | 331 | PF00017 | 0.455 |
LIG_SH2_STAP1 | 165 | 169 | PF00017 | 0.260 |
LIG_SH2_STAP1 | 199 | 203 | PF00017 | 0.360 |
LIG_SH2_STAP1 | 297 | 301 | PF00017 | 0.277 |
LIG_SH2_STAT5 | 152 | 155 | PF00017 | 0.398 |
LIG_SH2_STAT5 | 18 | 21 | PF00017 | 0.374 |
LIG_SH2_STAT5 | 270 | 273 | PF00017 | 0.425 |
LIG_SH3_2 | 25 | 30 | PF14604 | 0.325 |
LIG_SH3_3 | 22 | 28 | PF00018 | 0.331 |
LIG_SH3_3 | 300 | 306 | PF00018 | 0.427 |
LIG_SUMO_SIM_par_1 | 141 | 147 | PF11976 | 0.260 |
LIG_TRAF2_1 | 126 | 129 | PF00917 | 0.283 |
LIG_WRC_WIRS_1 | 175 | 180 | PF05994 | 0.320 |
LIG_WW_1 | 306 | 309 | PF00397 | 0.585 |
MOD_CDK_SPK_2 | 299 | 304 | PF00069 | 0.472 |
MOD_CDK_SPxxK_3 | 278 | 285 | PF00069 | 0.445 |
MOD_CK1_1 | 177 | 183 | PF00069 | 0.360 |
MOD_CK1_1 | 206 | 212 | PF00069 | 0.353 |
MOD_CK2_1 | 102 | 108 | PF00069 | 0.320 |
MOD_CK2_1 | 123 | 129 | PF00069 | 0.275 |
MOD_GlcNHglycan | 179 | 182 | PF01048 | 0.360 |
MOD_GlcNHglycan | 291 | 294 | PF01048 | 0.215 |
MOD_GlcNHglycan | 33 | 36 | PF01048 | 0.236 |
MOD_GlcNHglycan | 88 | 91 | PF01048 | 0.177 |
MOD_GSK3_1 | 170 | 177 | PF00069 | 0.320 |
MOD_N-GLC_2 | 266 | 268 | PF02516 | 0.440 |
MOD_NEK2_1 | 14 | 19 | PF00069 | 0.408 |
MOD_NEK2_1 | 198 | 203 | PF00069 | 0.403 |
MOD_PIKK_1 | 206 | 212 | PF00454 | 0.294 |
MOD_PKA_1 | 163 | 169 | PF00069 | 0.177 |
MOD_PKA_2 | 163 | 169 | PF00069 | 0.200 |
MOD_PKA_2 | 72 | 78 | PF00069 | 0.260 |
MOD_PKB_1 | 259 | 267 | PF00069 | 0.457 |
MOD_Plk_1 | 102 | 108 | PF00069 | 0.301 |
MOD_Plk_1 | 170 | 176 | PF00069 | 0.261 |
MOD_Plk_1 | 50 | 56 | PF00069 | 0.260 |
MOD_Plk_2-3 | 102 | 108 | PF00069 | 0.320 |
MOD_Plk_4 | 102 | 108 | PF00069 | 0.295 |
MOD_Plk_4 | 171 | 177 | PF00069 | 0.261 |
MOD_Plk_4 | 203 | 209 | PF00069 | 0.485 |
MOD_Plk_4 | 242 | 248 | PF00069 | 0.285 |
MOD_ProDKin_1 | 278 | 284 | PF00069 | 0.457 |
MOD_ProDKin_1 | 299 | 305 | PF00069 | 0.437 |
MOD_SUMO_rev_2 | 144 | 151 | PF00179 | 0.398 |
TRG_ENDOCYTIC_2 | 251 | 254 | PF00928 | 0.266 |
TRG_ENDOCYTIC_2 | 297 | 300 | PF00928 | 0.520 |
TRG_ENDOCYTIC_2 | 309 | 312 | PF00928 | 0.525 |
TRG_ENDOCYTIC_2 | 327 | 330 | PF00928 | 0.554 |
TRG_ER_diArg_1 | 162 | 164 | PF00400 | 0.329 |
TRG_ER_diArg_1 | 187 | 189 | PF00400 | 0.210 |
TRG_ER_diArg_1 | 259 | 261 | PF00400 | 0.342 |
TRG_ER_diArg_1 | 329 | 332 | PF00400 | 0.428 |
TRG_ER_diArg_1 | 98 | 100 | PF00400 | 0.354 |
TRG_NLS_MonoExtC_3 | 327 | 333 | PF00514 | 0.381 |
TRG_Pf-PMV_PEXEL_1 | 140 | 144 | PF00026 | 0.260 |
TRG_Pf-PMV_PEXEL_1 | 317 | 322 | PF00026 | 0.588 |
TRG_Pf-PMV_PEXEL_1 | 99 | 103 | PF00026 | 0.353 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N0P3S0 | Leptomonas seymouri | 75% | 100% |
A0A0S4KJA2 | Bodo saltans | 51% | 100% |
A0A1X0NVZ2 | Trypanosomatidae | 58% | 100% |
A0A3Q8IGB4 | Leishmania donovani | 80% | 100% |
A0A422NWY6 | Trypanosoma rangeli | 55% | 100% |
A4I125 | Leishmania infantum | 80% | 100% |
C9ZW84 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 54% | 100% |
E9AX62 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 79% | 100% |
Q3T0T0 | Bos taurus | 29% | 100% |
Q4QAB4 | Leishmania major | 78% | 100% |
V5B577 | Trypanosoma cruzi | 56% | 97% |